<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744081</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG-R1</org_study_id>
    <nct_id>NCT00744081</nct_id>
  </id_info>
  <brief_title>Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>Open-Label Multicenter Trial of GlivecÂ® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to show superiority in complete responses of combination therapy
      MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control
      which was treated with MTC alone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Anticipated">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.</measure>
  </primary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>AML</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glivec</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AraC</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory AML after primary therapy

          -  First relapse after a safe previous diagnosis of de novo or secondary AML

          -  Age &gt; 18 years

          -  Serum bilirubin &lt; 2.0 mg/dl

          -  Serum creatinine &lt; 1.5 times the normal value or a creatinine clearance &gt; 60 ml/min

          -  ECG and heart echography prior to start of therapy without severe findings

          -  Overall condition &lt; 2 according to ECOG criteria

          -  Life expectancy &gt; 6 weeks

          -  Written informed consent by patients with full legal capacity

        Exclusion Criteria:

          -  Serious secondary disease (clinically relevant cardiac disease, chronic- obstructive
             pulmonary disease, hepatic dysfunction, renal insufficiency)

          -  Active secondary neoplasia (exception: adequately treated basalioma or epidermoid
             cancer and cervical carcinoma)

          -  Known hypersensitivity to topoisomerase-I inhibitors

          -  Overall condition &gt; 2 according to ECOG criteria

          -  Pregnant/breast feeding women

          -  Serious intercurrent infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lothar Bergmann, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Frankfurt, Medical Dept. II</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lothar Bergmann, MD, PhD</last_name>
    <email>L.Bergmann@em.uni-frankfurt.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Frankfurt, Medical Dept. II</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leukemia-trials.eu</url>
    <description>(European Leukemia Trial Registry)</description>
  </link>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <last_update_submitted>August 28, 2008</last_update_submitted>
  <last_update_submitted_qc>August 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Lothar Bergmann</name_title>
    <organization>J. W. Goethe University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

